Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Dr. Karl Thomae Gmbh

Centrexion Therapeutics Corporation

Other

Boehringer Ingelheim Pharma Kg

Karl Thomae Gmbh

Novo Nordisk A/s

Karl Thomas Gmbh

Klaus Rudolf

Henri Doods

Dirk Stenkamp

Stephan Georg Mueller

Philipp Lustenberger

Gerhard Schaenzle

Kirsten Arndt

Wolfgang Eberlein

Wolfhard Engel

Marco Santagostino

Georg Dahmann

Raimund Kuelzer

Thierry Bouyssou

Alexander Dreyer

Andreas Schnapp

Fabio Paleari

Matthias Grauert

Christoph Hoenke

Ingo Konetzki

Marcus Schindler

Gerhard Mihm

Daniel Bischoff

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Michael Entzeroth

Dirk Gottschling

Annekatrin Charlotte Heimann

Eckhart Bauer

Riccardo Giovannini

Rudolf Hurnaus

Marco Ferrara

Iain Lingard

Rocco Mazzaferro

Wolfgang Wienen

Kai Gerlach

Gerhard Hallermayer

Klaus-Dieter Willim

Kurt Schromm

Leo Thomas

Ralf Lotz

Sabine Pestel

Frank Buettner

Bernd Wellenzohn

Claudia Heine

Hermann Schollenberger

Stefan Just

Yunhai Cui

Heike-Andrea Wieland

Knud Erik Andersen

Dieter Wiedenmayer

Bernd Peschke

Juergen Mack

Norbert Mayer

Martin Lenter

Ralf R H Lotz

Bernd Krist

Thorsten K Oost

Helmut Pieper

Stefan Peters

Horst Dollinger

Franz Esser

Gerd Schnorrenberg

Gunter Trummlitz

Christian Eickmeier

Christian Gnamm

Florencio Zaragoza Dorwald

Bernhard Schmid

Lothar Kussmaul

Jan Magnus Kriegl

Ulla Grove Sidelmann

Jurgen Krause

Stephan Georg Muller

Heike Andrea Wieland

Harald Ziegler

Armin Heckel

Georg Speck

Henning Priepke

Joerg Kley

Roland Pfau

Ingrid Pettersson

Michael Paul Pieper

Gunther Engelhardt

Stefan Scheuerer

Steffen Breitfelder

Birgitte Langer Eriksen

Bernd Nosse

Heather Tye

Michel Pairet

Alexander Heim-Riether

Birgitte Schjellerup Wulff

Adriaan De Jonge

Florencio Zaragoza Dörwald

Holger Hoesch

Juergen Prestle

Alexander Heifetz

Stephan-Georg Mueller

Phillip Lustenberger

Christopher John Brown

Natacha Prevost

The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)

Modulators of complex I

3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.

Somatostatin receptor subtype 4 (SSTR4) agonists

The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention. 

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Pyrimidine derivatives which are CGRP&#x2014;antagonists

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R, R, Rhave meanings given in the description.

Compounds

Substituted triazoles useful as mGlu5 receptor modulators

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R, R, R, Rhave meanings given in the description.

Growing community of inventors

Warthausen, Germany

Klaus Rudolf